Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) reported third-quarter financial results after the market close on Tuesday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/07/b46704797/starbucks-reports-q3-fiscal-year-2025-results">from the report</a>.



SBUX stock is ticking upward now. <a href="https://www.benzinga.com/quote/SBUX" target="_blank" rel="noreferrer noopener">See the chart here.</a>



Q3 Earnings: Starbucks reported third-quarter revenue of $9.46 billion, beating <a href="https://www.benzinga.com/quote/SBUX/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a> of $9.29 billion. The coffee giant reported third-quarter adjusted earnings of 50 cents per share, missing analyst estimates of 65 cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.



Consolidated net revenue was up 4% on a year-over-year basis. Global comparable store sales declined 2%, driven by a 2%&nbsp;decline in comparable transactions, partially offset by a&nbsp;1%&nbsp;increase in average ticket. Comparable store sales fell 2% in North America and were approximately flat internationally. The company said comparable store sales in China were up 2% in the quarter.



Starbucks opened 308 net new stores in&nbsp;the third quarter and ended the quarter with 41,097 total locations. The company said it had approximately $4.17 billion in cash and cash equivalents at quarter&#8217;s end.



&#8220;We&#8217;ve fixed a lot and done the hard work on the hard things to build a strong operating foundation, and based on my experience of turnarounds, we are ahead of schedule,&#8221; said&nbsp;Brian Niccol, chairman and CEO of Starbucks.



&#8220;In 2026, we&#8217;ll unleash a wave of innovation that fuels growth, elevates customer service and ensures everyone experiences the very best of Starbucks.&#8221;



Starbucks' board declared a cash dividend of 61 cents per share, payable on Aug. 29 to shareholders of record as of Aug. 15.



Niccol and CFO Cathy Smith will host a conference call to further discuss the quarter at 4:15 p.m. ET.



SBUX Price Action: <a href="https://www.benzinga.com/quote/SBUX" target="_blank" rel="noreferrer noopener">Starbucks shares</a> were up 4.45% in after-hours, trading at $97.10 at the time of publication on Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.



Read Next:



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46654908/ai-speeds-up-work-but-just-leads-to-coffee-breaks-says-accenture-exec-who-urges-reinventing-roles-not-just-tools">AI Speeds Up Work—But Just Leads To Coffee Breaks, Says Accenture Exec Who Urges Reinventing Roles, Not Just Tools</a></li>
</ul>



Photo: Cloudy Design/Shutterstock.com

Earnings

News

Restaurants

Movers

SBUX

Starbucks Q3 Earnings: Revenue Beat, EPS Miss, Turnaround Efforts 'Ahead Of Schedule'

Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) reported third-quarter financial results <a href="https://www.benzinga.com/earnings">after market close Tuesday</a>. Here are the key highlights.



<ul class="wp-block-list">
<li>V is showing strength near its 52-week high. <a href="https://www.benzinga.com/quote/V" target="_blank" rel="noreferrer noopener">Track live prices here.</a></li>
</ul>



What Happened: Visa reported third-quarter net revenue of $10.17 billion, up 14% year-over-year. The revenue total beat a Street consensus estimate of $9.82 billion according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0729">from Benzinga Pro.</a>



The company's revenue growth was helped by year-over-year growth in payments volume, cross-border volume and processed transactions.



Visa reported quarterly adjusted earnings per share of $2.98, beating a Street consensus estimate of $2.83.



Payments volume was up 8% year-over-year in the quarter with the company's processed transactions up 10% year-over-year.



Visa reported cross-border volume up 12% year-over-year.



"Visa delivered another strong quarter, with 14% net revenue growth, 12% GAAP EPS growth and 23% non-GAAP EPS growth," Visa CEO Ryan McInerney said. "Healthy business driver trends continued through the quarter and into the first few weeks of July."



Read Also: <a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46684911/how-to-earn-500-a-month-from-visa-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Visa Stock Ahead Of Q3 Earnings</a>



What's Next: McInerney said consumer spending is "resilient" and growth for discretionary and non-discretionary spending continues in the United States.



The CEO stated that the company's forward focus is on innovation and product development in areas such as AI and stablecoins. McInerney believes these items will help "shape the future of commerce" and bring value to shareholders.



V Price Action: Visa stock is down 1.1% to $346.44 in after-hours trading Tuesday versus a 52-week trading range of $254.51 to $375.51.



Read Next: 



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46657015/visa-disney-blackstone-health-care-stock-on-cnbcs-final-trades">Visa, Disney, Blackstone And A Health Care Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>



<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; Visa Earnings Call Q3 2025 &#x7C; $V &#x7C; WATCH LIVE" width="500" height="281" src="https://www.youtube.com/embed/Rx3R-GMugug?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div></figure>



Photo: Shutterstock

Trading Ideas

Visa Q3 Earnings Highlights: Double Beat, CEO Says Consumer Spending Remains 'Resilient'

If you're thinking markets look a little tired lately, you aren't alone. The S&amp;P 500 continues to set new highs on a weekly basis, and companies are still reporting strong earnings.



However, there are more than a few signs that this rally is getting long in the tooth. President Trump's trade deals with Japan and Europe haven't moved the needle much on U.S. indices, and S&amp;P 500 companies are reporting lower net profit margins in Q2 compared to Q1.



Oh, and the meme stocks are back, which doesn't exactly lend to the argument that we're still in the early innings of a market rally.



Only three sectors reported higher profit margins in Q2 than Q1: communications, tech, and financials. That makes undervalued financial stocks with strong dividends a great late bull market play for both growth and income.



Today we&#8217;re going over five finance firms with high Benzinga Edge Value scores that also offer steady dividend yields.



Let&#8217;s take a look.



<h2 class="wp-block-heading">How to Beat a Split Market, Live Wednesday, July 30 at 6 PM ET</h2>



Markets are at all-time highs, but not everything is working. This Wednesday, Tim Melvin, Anne-Marie Baiynd, and Ryan Faloona go live to reveal the income trades, trend setups, and undervalued stocks they're targeting right now. If you're done chasing headlines and want real strategy, don't miss it. <a href="https://events2.benzinga.com/bz-pro-webinar-wed-july30-2025-registration/?utm_campaign=073025-webinar&amp;&amp;utm_adType=sponsorad&amp;utm_ad=RD073025/?el=ResearchDaily&amp;he=%7B%7Bemail%7D%7D&amp;adt_ei=%7B%7Bemail%7D%7D&amp;utm_medium=newsletter">Register NOW, seats are limited</a>.



<h2 class="wp-block-heading">Lincoln National Corp.&nbsp;</h2>



<ul class="wp-block-list">
<li>Dividend Yield: 5.14%</li>



<li>Benzinga Edge Value Score: 96.76</li>
</ul>



Lincoln National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>) is a $6 billion market cap firm based outside of Philadelphia that offers a variety of life insurance and retirement services (and also sponsors the stadium of the Super Bowl champion Eagles). The company's stock has basically traded flat over the last five years, but it's up more than 10% already this year and appears to have found a long-term support level after an extended period of sideways trading.



<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXceaT3x2JhP4F8iqieDbYDCGo3YCpcrPcq7kQelFiMj0RndkGcxlY3oIl7ZHmdB7XlC2cBXgy5IFZisRz_FLz1z6KLr1JGq0Il1nYdNTj--kuLprwl4wr-nb5u7_h8hvMjrone3?key=-TeQJQtrZgIPf2TWSw0kBg" alt=""/></figure>



LNC doesn't have the dividend track record that some of the companies listed below have, but it&#8217;s a healthy 5% yield with a dividend payout rate of just 25%. Analysts still rate the stock as a consensus &#8220;Hold&#8221; following an EPS beat and a narrow revenue miss in Q1, but three different firms have upped their price targets in July, including Wells Fargo and JPMorgan Chase. Lincoln National also received an $825 million cash infusion from Bain Capital, which now owns 9.9% of the company.



<h2 class="wp-block-heading">Universal Insurance Holdings Inc.&nbsp;</h2>



<ul class="wp-block-list">
<li>Dividend Yield: 2.26%</li>



<li>Benzinga Edge Value Score: 94.27</li>
</ul>



Universal Insurance Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UVE#NYSE">UVE</a>) is a small-cap provider of personal residential insurance policies for owners and renters. Despite a market capitalization of just $647 million and a dividend history of only 18 months, UVE offers a strong 2.8% yield with a manageable payout ratio of 28%. It also released an earnings report on July 24, impressing the market by beating revenue expectations by nearly 35%. The $596 million in sales was the highest quarterly figure the company has produced since going public in 2007.



<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXdSxAJTWk49ad-ux0vdcqqSRBVkuzpisSYzut4d8rbP6JXxz2N6WHXHn721MKygEHDGwsawRCI7ghNkc6kcK-RcX26HSD8ndzMhQBBEpfZx_hb9adLTe4vg9zVA5NRCOBbYAENI3A?key=-TeQJQtrZgIPf2TWSw0kBg" alt=""/></figure>



The stock sold off following the earnings beat, but this could be profit-taking following a 20% gain over the last 12 months. UVE shares found support at the 200-day moving average, and the Relative Strength Index (RSI) has triggered an Oversold signal. This could be a good buying opportunity in a company that's exceeding sales expectations and has plenty of room to increase its dividend in the years ahead.



<h2 class="wp-block-heading">Old Republic International Corp.&nbsp;</h2>



<ul class="wp-block-list">
<li>Dividend Yield: 3.24%</li>



<li>Benzinga Edge Value Score: 89.66</li>
</ul>



Old Republic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORI#NYSE">ORI</a>) is a $8.9 billion market cap insurer that offers home and auto insurance for both commercial and private customers, along with aviation, workers&#8217; compensation, and other general liability policies. Unlike Lincoln National and Universal Insurance, Old Republic is a Dividend Aristocrat with a 45-year history of annual payout increases, currently yielding 3.2% with a dividend payout ratio of 39.7%. The company also reported Q2 2025 earnings on July 24, beating expectations on both EPS and revenue, including impressive revenue growth of 10% year-over-year (YOY).



<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXcwfFDNYCw4xKp-W_c7rkPuYrseVQa3RZenFwFBkx35Y1lb08pWhcDMJnpskMDM3BAS7T6e11FowdvXN4SChtjus8ARDiY8lzD5ZImTigbkAO9Wvp1WWVvPRkDV0BFuIGPORhjT?key=-TeQJQtrZgIPf2TWSw0kBg" alt=""/></figure>



ORI shares have ridden a steady upward trajectory since late 2023, bouncing off the blue support line above multiple times over the last two years. The stock is once again approaching this support level, and the RSI is creeping closer and closer to the Oversold threshold of 30. A buying opportunity could be on the horizon if the Oversold signal is triggered at the long-term support level.



<h2 class="wp-block-heading">Jeffries Financial Group Inc.&nbsp;</h2>



<ul class="wp-block-list">
<li>Dividend Yield: 2.78%</li>



<li>Benzinga Edge Value Score: 85.21</li>
</ul>



Jeffries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is the first market maker on our list, offering investment banking services to clients across North America, Europe, and Asia. The stock has a market capitalization of $11.9 billion and pays a dividend yield of 2.87%, with a payout ratio of 60%. It has now raised payouts for 2024 and 2025.



<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXdGXEqvHOGlm91OJetXzycc7ivZCmB_fwco5w8unLgBE_CkSdcCA6PhlD4yqt5cT6-d_hl851_reBZjq4ZhGr-T5nG6HGYx2lbhsGJB48Do-fnzJK1rp3alhHXKmQmQhbiuWVGf9w?key=-TeQJQtrZgIPf2TWSw0kBg" alt=""/></figure>



Jeffries missed EPS and revenue expectations during its Q2 2025 release back in June, but the stock may have finally found its bottom back in April. Once the Trump reciprocal tariffs were canceled, the stock bounced off an RSI Oversold signal and gained more than 22% between April and July. Shares are once again approaching the new support level, and shrewd investors may consider taking a shot at adding to their holdings here.



<h2 class="wp-block-heading">The Hanover Insurance Group Inc.&nbsp;</h2>



<ul class="wp-block-list">
<li>Dividend Yield: 2.18%</li>



<li>Benzinga Edge Value Score: 83.21</li>
</ul>



The Hanover Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) pays the smallest yield of any stock on our list, but it's also got something our previous four entries lacked: momentum. In addition to a solid Value rating, THG scores a 74.44 rating on Benzinga Edge's Momentum scale, indicating an undervalued stock that still has more upside ahead. The company has also raised its annual dividend payouts for 20 consecutive years, with a payout rate of just 30%.



<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXdWst3TaEtH82OHyVn0FVmgQSKDNFbfy952HJlqm6qEmMjj7eNiDebZRt-DNu0cA-EfbzpauGPb5AaRoPqzMe4BkW5U87RVyCr0fDaMNOV5g7hqO941gzB7h5cthM5SRfxk5WkM7Q?key=-TeQJQtrZgIPf2TWSw0kBg" alt=""/></figure>



Hanover reports earnings on July 30, and analysts will be looking to see if the company can build on its previous EPS beat from Q1. Revenue slightly missed expectations, but still grew 3.4% YOY. Analysts at Keefe, Bruyette, and Woods upgraded the stock from Hold to Buy this month. In addition to strong fundamentals and a robust dividend, the stock has been in an uptrend since a Golden Cross breakout in late 2023. Currently, the price appears to be consolidating around the 200-day moving average, and an impressive earnings report could propel the stock into its next leg up.



Editorial content from our expert contributors is intended for the general public and does not constitute individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.



Image: Shutterstock

Opinion

5 Undervalued Dividend Stocks To Buy As Rally Gets Overextended

When President Donald Trump <a href="https://www.benzinga.com/topic/tariffs">threatened to hike tariffs</a> on all U.S. trading partners at the start of the year, a rush of foreign goods flooded into the country as businesses scrambled to stockpile inventory ahead of higher costs.



<ul class="wp-block-list">
<li>USO ETF&#8217;s momentum accelerates. <a href="https://www.benzinga.com/quote/USO">Track it now here.</a></li>
</ul>



That front-loading behavior distorted economic data, with the U.S. economy shrinking 0.5% in the first quarter—the worst performance in three years. Trump's aggressive tariff rhetoric initially seemed to backfire, fueling concerns it was doing more harm than good.



In fact, the record $390 billion trade deficit logged in the first quarter of 2025 was largely a byproduct of the very habit tariffs were meant to discourage: over-reliance on foreign goods.



Each of the first three months of the year posted the worst monthly trade gaps on record.



Now, the script has flipped. 



With tariffs taking effect after April 2 Liberation Day, imports are falling quickly—and the U.S. trade deficit is shrinking much faster than most economists projected.



Trump is treating it as a first victory lap—framing his aggressive tariff strategy not merely as leverage, but as a concrete policy success now delivering the first economic gains.



<h3 class="wp-block-heading">US Trade Deficit Narrows Sharply In June</h3>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="560" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29145844/image-464-1024x560.png" alt="" class="wp-image-1005823" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29145844/image-464-1024x560.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29145844/image-464-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29145844/image-464-768x420.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29145844/image-464-1536x840.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29145844/image-464-2048x1120.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



According to Census Bureau data released Tuesday, the U.S. goods trade deficit narrowed by $10.4 billion in June to $86 billion. 



That's far better than Wall Street's forecast of $98.4 billion and marks the smallest trade gap since September 2023.



Imports dropped 4.2% month over month to $264 billion, led by sharp declines in consumer goods, down 12.4% to $58 billion, and industrial supplies, down 5.5% to $48 billion. Capital goods imports held steady near $91 billion.



On the export side, the picture was more stable. Total outbound shipments slipped just 0.6% to $178.2 billion, supported by a 4.7% jump in capital goods exports and a 4% rise in food and beverages.



<h2 class="wp-block-heading">What Comes Next? A Data Storm</h2>



Tuesday's trade data is only the first of several key economic reports this week that could shape investor expectations and Federal Reserve policy.



On Wednesday, the Bureau of Economic Analysis will release the advance second-quarter GDP estimates, with median consensus from Wall Street economists expecting a 2.4% rise. 



"Q2 GDP is likely to rise by 2.3% quarter-over-quarter annualized, compared to -0.5% in Q1," Bank of America economist Pedro Diaz said. "That increase is primarily due to a reversal of the Q1 import surge driven by tariff front-loading."



Bill Adams, chief economist at Comerica Bank, is more optimistic. "June's drop in the trade deficit and the rise in inventories boost the outlook for Q2," he said. "We forecast a 2.9% annualized increase, mostly thanks to the collapse in imports."



The Federal Reserve is expected to hold interest rates steady on Wednesday at 4.25%-4.5%. But two FOMC members—Governors Michelle Bowman and Christopher Waller—may dissent in favor of early rate cuts, adding new tension to Chair Jerome Powell's press conference.



Diaz thinks Powell may remain cautious: "He would prefer to see July's data before guiding markets at Jackson Hole."



Then on Thursday comes June's Personal Consumption Expenditures (PCE) inflation print—arguably the Fed's most-watched indicator. Economists expect the core PCE to rise to 2.5% year-over-year, up from 2.3%.



The week ends with July's jobs report, where consensus calls for 110,000 new payrolls and a slight uptick in the unemployment rate to 4.2%. 



Read Next:



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46693997/wall-street-earnings-preview-microsoft-apple-meta-amazon-mastercard-visa">$19.5 Trillion Earnings Blitz: Wall Street Faces Make-Or-Break 72 Hours </a></li>
</ul>



Photo: Shutterstock

Analyst Color

Government

Macro Economic Events

Regulations

Econ #s

Economics

Analyst Ratings

Trump Toasts Tariff Victory As Economists Quietly Junk Their Trade Forecasts

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is one of the top-performing Magnificent 7 stocks in 2025 and could highlight its AI investments when the company reports second-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Wednesday.</a>



Here are the earnings estimates, what experts are saying ahead of the report, and key items to watch.



Earnings Estimates: Analysts expect Meta Platforms to report second-quarter revenue of $44.6 billion, up from $39.1 billion in last year's second quarter, according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0729"> from Benzinga Pro.</a>



The company has beaten analyst estimates for revenue in 11 straight quarters.



Analysts expect the company to report second-quarter earnings per share of $5.86, up from $5.16 in last year's second quarter. The company has beaten analyst estimates for earnings per share in nine straight quarters.



Meta's <a href="https://www.benzinga.com/news/earnings/25/04/45117948/meta-q1-earnings-eps-beat-revenue-up-16-ai-approaches-1-billion-monthly-actives-capital-expenditures-forecast-raised">guidance calls for</a> second-quarter revenue to be in a range of $42.5 billion to $45.5 billion.



Read Also: <a href="https://www.benzinga.com/markets/tech/25/07/46654484/mark-zuckerbergs-meta-shuts-down-eu-political-ads-on-facebook-instagram-whatsapp-calls-new-rules-unworkable">Mark Zuckerberg&#8217;s Meta Shuts Down EU Political Ads On Facebook, Instagram, WhatsApp — Calls New Rules &#8216;Unworkable&#8217;</a>



What Experts are Saying: Freedom Capital Markets Chief Global Strategist Jay Woods said Meta stock has had mild reactions after the last four quarterly reports, with three rallies and one sell-off, each move being 5% or less.



Woods <a href="https://jaywoods.substack.com/">said </a>the implied volatility for the current earnings day is a move of +/- 7.4%.



As for what investors are watching in the current earnings report, Woods highlights two key areas.



"How is ad growth adding to its bottom line? What is the future CapEx spend looking like and has their AI spend started to see a return on its investment?" Woods asks.



The market expert said Ad growth and AI spending will be the keys to watch.



Bank of America Securities analyst Justin Post highlighted Meta's aggressive AI spending and investments on grabbing top AI talent from other companies as an item to watch in the <a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46668016/metas-strong-revenues-may-offset-concerns-over-soaring-ai-investments-analyst">company's quarterly expenses.</a>



The analyst reiterated a Buy rating and $775 price target ahead of the report.



Post said items to watch include the company's investment in Scale AI and the formation of the company's Super Intelligence team.



The analyst expects Meta to report strong guidance with AI-driven improvements helping ad revenue along with increased monetization for Threads, WhatsApp and messaging.



Key Items to Watch: A <a href="https://www.benzinga.com/news/social-media/25/07/46333856/musk-vs-zuckerberg-two-richest-men-battle-over-daily-social-media-users">report in July</a> highlighted Meta's Threads platform growing to more than 350 million registered users and having 115.1 million daily active users on the mobile app.



The latest mobile daily active user numbers put Threads close to the same total as rival X, although Threads significantly trails X in web traffic.



Threads could be the next platform for Meta to focus on monetization with its growing user base and metrics.



In the first quarter, Meta Platforms saw its family daily active people total up 6% year-over-year to 3.43 billion.



The company reported a 5% year-over-year increase in the number of ad impressions and a 10% year-over-year increase in the average price per ad. Investors and analysts will be closely watching these metrics.



Meta CEO Mark Zuckerberg called the first quarter "a strong start to an important year." Zuckerberg said Meta AI had around 1 billion monthly active users at the time.



Investors and analysts will be looking for updates on important milestones like this as the company spends more on AI. <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning-bzwidget" target="_blank" rel="noreferrer noopener"></a>



META Price Action: Meta stock is down 0.9% to $710.87 on Tuesday versus a 52-week trading range of $450.80 to $747.90. Meta stock is up 18.6% year-to-date in 2025.



Read Next: 



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46580004/trumps-ai-action-plan-to-unleash-4th-industrial-revolution-dan-ives-picks-6-stock-winners">Trump&#8217;s AI Action Plan To Unleash &#8216;4th Industrial Revolution&#8217;: Dan Ives Picks 6 Stock Winners</a></li>
</ul>



Photo: Skorzewiak/Shutterstock

Long Ideas

Social Media

Previews

Tech

Meta Q2 Preview: 11 Straight Revenue Beats On Line With Stock Near All-Time Highs

With U.S. major stock indices at record highs and investor optimism running hot, Wall Street is entering one of the most critical 72-hour<a href="https://www.benzinga.com/markets"> stretches of the year. </a>



<ul class="wp-block-list">
<li>SPY ETF hit a new record high on July 29. <a href="https://www.benzinga.com/quote/SPY">Check the price action here.</a></li>
</ul>



Between Tuesday and Thursday, companies representing a combined $19.5 trillion in market capitalization are set to report quarterly earnings—offering a litmus test for the sustainability of the tech-led rally. 



Six companies alone, including four Magnificent Seven giants, account for $12 trillion of that total. 



According to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;estimates, here's a look at the key earnings and revenue reports this week that could drive major market moves.



<h3 class="wp-block-heading">Tuesday, July 29</h3>



Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) — After Market



<ul class="wp-block-list">
<li>Expected EPS: $2.83 (vs. $2.42 prior), up by 17.4%</li>



<li>Expected Revenue: $10.33 billion (vs. $8.9B prior), up by 16.1%</li>



<li>Market Cap: $714.2 billion</li>



<li>Quarter: Q3 2025</li>



<li>Year-to-date performance: 12.66%</li>
</ul>



Read more: <a href="https://www.benzinga.com/insights/earnings/25/07/46660296/a-peek-at-visas-future-earnings">A Peek at Visa&#8217;s Future Earnings</a>



<h3 class="wp-block-heading">Wednesday, July 30</h3>



Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) — After Market



<ul class="wp-block-list">
<li>Expected EPS: $3.37 (vs. $2.95 prior), up by 14.2%</li>



<li>Expected Revenue: $73.8 billion (vs. $64.7B prior), up by 14%</li>



<li>Market Cap: $3.82 trillion</li>



<li>Quarter: Q4 2025</li>



<li>Year-to-date performance: 22.1%</li>
</ul>



In a note shared Tuesday, Goldman Sachs analyst Kash Rangan said that "Microsoft is well-positioned to capitalize as Gen-AI moves into platform and application layers, just as it did during the cloud transition."



Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) — After Market



<ul class="wp-block-list">
<li>Expected EPS: $5.86 (vs. 5.16 prior), up by 13.3%</li>



<li>Expected Revenue: $44.58 billion (vs. $39.07B prior), up by 13.7%</li>



<li>Market Cap: $1.82 trillion</li>



<li>Quarter: Q2 2025</li>



<li>Year-to-date performance: 21.88%</li>
</ul>



Read more: <a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46668016/metas-strong-revenues-may-offset-concerns-over-soaring-ai-investments-analyst">Meta&#8217;s Strong Revenues May Offset Concerns Over Soaring AI Investments: Analyst</a>



<h3 class="wp-block-heading">Thursday, July 31</h3>



Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) — Pre-Market



<ul class="wp-block-list">
<li>Expected EPS: $4.02 (vs. $3.59 prior), up by 12%</li>



<li>Expected Revenue: $7.95 billion (vs. $7.00B prior) up by 13.4%</li>



<li>Market Cap: $524.4B</li>



<li>Quarter: Q2 2025</li>



<li>Year-to-date performance: 7.94%</li>
</ul>



Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) — After Market



<ul class="wp-block-list">
<li>Expected EPS: $1.42 (vs. $1.40 prior), up by 1.4%</li>



<li>Expected Revenue: $88.93B (vs. $85.8B prior), up by 3.6%</li>



<li>Market Cap: $3.19T</li>



<li>Quarter: Q3 2025</li>



<li>Year-to-date performance: -15%</li>
</ul>



&#8220;Apple should deliver a revenue and EPS beat, driven by double-digit growth in Services, strength across Products including iPhones, Mac, iPad, and Wearables; and better-than-expected gross margins reflecting on better tariff-related costs and forex headwinds,&#8221; said Goldman Sachs&#8217; analyst Michael Ng.



According to the analyst, iPhone upgrade demand over the next 12 months should benefit from stronger U.S. carrier promotions and new product innovations, including Apple Intelligence and upcoming form factor changes like the iPhone 17 Air and a foldable iPhone 18.



Goldman Sachs maintains a Buy rating on Apple stock with a 12-month price target of $251, suggesting a potential 20% upside from current levels.



Read more: <a href="https://www.benzinga.com/markets/tech/25/07/46680504/apple-faces-18-month-deadline-to-deliver-on-ai-says-analyst">Apple To Shut Down China Retail Store For First Time Ever, Citing Shifting Mall Landscape Amid Consumer Slowdown</a>



Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) — After Market



<ul class="wp-block-list">
<li>Expected EPS: $1.31 (vs. $1.26 prior), up by 4.8%</li>



<li>Expected Revenue: $161.87 billion (vs. $147.98B prior), up by 9.4%</li>



<li>Market Cap: $2 trillion</li>



<li>Quarter: Q2 2025</li>



<li>Year-to-date performance: 5.5%</li>
</ul>



Read Next:



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46686037/nvidia-is-now-worth-twice-tesla-amd-palantir-and-intel-combined">Nvidia Is Now Worth Twice Tesla, AMD, Palantir, And Intel Combined </a></li>
</ul>



Image created using artificial intelligence via Midjourney.

Equities

Large Cap

AAPL

AMZN

MSFT

$19.5 Trillion Earnings Blitz: Wall Street Faces Make-Or-Break 72 Hours

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) suffered its worst trading session on record Tuesday, plunging as much as 25% in European markets after issuing a surprise profit warning tied to its blockbuster obesity drug Wegovy and <a href="https://www.benzinga.com/topic/weight-loss">appointing a new CEO</a>.



<ul class="wp-block-list">
<li>NVO stock is moving fast. <a href="https://www.benzinga.com/quote/NVO">Check the latest price here. </a></li>
</ul>



The Danish pharmaceutical giant now expects 2025 sales to grow 8%–14%, down from a previous range of 13%–21%, and has cut its operating profit forecast to 10%–16%, from 16%–24%. That marks the second guidance cut of the year.



Shares have now fallen 35% year-to-date and are down a staggering 65% from their June 2023 all-time high, wiping out billions in market cap.



Goldman Sachs analyst James Quigley wrote that the reduced expectations were driven by "no change in the compounded semaglutide headwinds and slower-than-expected commercial progress for both Ozempic and Wegovy, with reimbursement access not progressing as planned."



<h3 class="wp-block-heading">Novo Nordisk Crashes 26% in Worst Day On Record</h3>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="560" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-1024x560.png" alt="" class="wp-image-1005185" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-1024x560.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-768x420.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-1536x840.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29090951/image-75-1-2048x1120.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



<h3 class="wp-block-heading">Key Drivers: Compounding, Competition And Slow Reimbursement</h3>



The company blamed ongoing use of compounded semaglutide drugs in the U.S. for undercutting demand for Wegovy, with the CFO&#8217;s estimates suggesting over 1 million patients are on off-brand versions.



Novo has sued telehealth firms like Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) for marketing what it calls knockoff Wegovy, warning about the risks of illicit or unregulated active ingredients.



Meanwhile, lower-than-expected growth for Ozempic in the U.S. diabetes market and sluggish Wegovy penetration overseas also contributed to the downgrade.



"We expect investors to remain cautious on the outlook for Novo and the obesity market, particularly given the slow resolution of compounding, which has been pushed into at least 2026, and due to concerns about potential further price cuts in order to drive access," Quigley said



<h3 class="wp-block-heading">Leadership Shakeup</h3>



Alongside the downgrade, Novo Nordisk appointed Maziar Mike Doustdar as CEO, effective Aug. 7. Currently head of international operations, Doustdar replaces Lars Fruergaard Jorgensen, ousted in May.



Analysts say Doustdar's challenge will be to expand U.S. Wegovy adoption while scaling international markets and managing intensifying competition from Eli Lilly Co.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound.



<h3 class="wp-block-heading">Is the Weight-Loss Drug Trade Topping Out?</h3>



With Novo's crash, a broader question looms: Is the weight-loss trade entering correction territory? 



The sharp shift in investor sentiment suggests that valuation multiples may no longer be justified if volume growth stalls and compounding remains unresolved into 2026.



NVO Price Action: Novo Nordisk shares were down 20.36% at $54.95 at the time of publication on Tuesday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>



Read Next:



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46641084/wall-street-stock-bubble-2025">Is A Stock Market Crash Imminent? Bubble Warnings Grow Louder </a></li>
</ul>



Photo: JHVEPhoto / Shutterstock.com

Eurozone

HIMS

Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting?

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of <a href="https://www.benzinga.com/markets/earnings/25/07/46693997/wall-street-earnings-preview-microsoft-apple-meta-amazon-mastercard-visa">earnings and macro events.</a>



<ul class="wp-block-list">
<li>MAGS ETF is up 50% since April&#8217;s tariff-driven low. <a href="https://www.benzinga.com/quote/MAGS">Track it now here.</a></li>
</ul>



Roughly $19.5 trillion in market value — led by four Magnificent Seven names: Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) — is set to report earnings by Thursday after market close.



Meanwhile, the Federal Reserve is widely expected to keep rates steady at 4.25%-4.5% on Wednesday, though growing market chatter points to possible dissent in favor of early cuts.



A 90-day extension of the U.S.-China trade truce remains on the table, said U.S. Secretary of Commerce Howard Lutnick.



Attention will then shift to Thursday's heavy macro lineup, including second-quarter GDP growth estimates and June's PCE inflation data, followed by July's jobs report on Friday — key inputs for the Fed's next move.



By midday in New York, the S&amp;P 500 slipped 0.1%, the Dow Jones Industrial Average declined 0.4%, and the Russell 2000 shed 0.7%. The Nasdaq 100 remained flat.



Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) surged past $175, breaching a major technical level and marking highs not seen since July 2014, making it one of the day's top tech performers. 



Shares of AMD have now rallied by 134% since April&#8217;s tariff-driven lows, outperforming NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)&#8217;s 105% gain during the same period.



The U.S. dollar extended its rally, on pace for a fourth consecutive gain after Monday's sharp move.



In commodities, oil prices stayed hot. WTI crude rose 1.6% to $67.75 per barrel, extending Monday's 2.4% jump and hitting a two-week high. Precious metals traded sideways as dollar strength continued to limit upside momentum.



Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged down 1% to $117,000, logging a second straight daily decline.



<h2 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h2>



<figure class="wp-block-table is-style-stripes"><table class="has-fixed-layout"><tbody><tr><td>Major Indices </td><td>Price</td><td>1-day % chg</td></tr><tr><td>Nasdaq 100</td><td>23,364.69</td><td>0.0%</td></tr><tr><td>S&amp;P 500</td><td>6,380.21</td><td>-0.1%</td></tr><tr><td>Dow Jones</td><td>44,657.34</td><td>-0.4%</td></tr><tr><td>Russell 2000</td><td>2,241.90</td><td>-0.7%</td></tr></tbody></table><figcaption class="wp-element-caption">Updated by 12:20 p.m. ET</figcaption></figure>



According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:



<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) was down 0.092% to $584.90.</li>



<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) slipped 0.4% to $446.42.</li>



<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;flattened at $567.97.</li>



<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.8% to $222.45.</li>



<li>The&nbsp;Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) underperformed, down 1.3%; the&nbsp;Real Estate&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 1.3%.</li>
</ul>



<h2 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h2>



<ul class="wp-block-list">
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) plunged 22.5% after the Danish pharma giant slashed guidance on its blockbuster Wegovy weight-loss drug, while also <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46688728/novo-nordisk-weight-loss-stock-eli-lilly-wegovy-ozempic">announcing a new CEO.</a></li>



<li>Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) surged more than 20% after announcing that the U.S. Food and Drug Administration signaled it could resume shipments of Elevidys.</li>
</ul>



Stocks reacting to quarterly results included:



<ul class="wp-block-list">
<li>Procter &amp; Gamble Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) flat at 0.0%</li>



<li>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) down 5.1%</li>



<li>Merck &amp; Co., Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) down 3.3%</li>



<li>Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) down 3.0%</li>



<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) down 11.8%</li>



<li>American Tower Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) down 3.0%</li>



<li>Royal Caribbean Cruises Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) down 5.0%</li>



<li>United Parcel Service, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) down 9.7%</li>



<li>Ecolab Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) down 4.7%</li>



<li>PayPal Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) down 9.3%</li>



<li>Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) down 6.9%</li>



<li>Norfolk Southern Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) down 3.5%</li>



<li>Carrier Global Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) down 11.0%</li>



<li>Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) up 13.2%</li>



<li>CBRE Group, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) up 9.1%</li>



<li>Sysco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) down 2.5%</li>



<li>DTE Energy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>) up 0.2%</li>



<li>SoFi Technologies, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) up 14.0%</li>



<li>Hubbell Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) down 2.6%</li>



<li>Incyte Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) up 8.6%</li>



<li>Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) down 8.4%</li>



<li>PJT Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJT#NYSE">PJT</a>) down 2.0%</li>



<li>Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) up 12.2%</li>



<li>JetBlue Airways Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) up 4.9%</li>
</ul>



Stocks scheduled to report earnings after Tuesday's close include BXP Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>), Caesars Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>), Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Essex Property Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>), Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), PPG Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>), Regency Centers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>), Republic Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>), Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), Teradyne Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), The Cheesecake Factory Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>), Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>), Pebblebrook Hotel Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>), Qorvo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) and Red Rock Resorts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>).



Read Now:



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/forex/25/07/46673546/us-eu-trade-deal-dollar-surge-trump">Trump&#8217;s Charm Offense In Europe Unleashes Dollar Thunder</a> Photo: Shutterstok<a href="https://www.benzinga.com/markets/forex/25/07/46673546/us-eu-trade-deal-dollar-surge-trump"> </a></li>
</ul>

Cryptocurrency

Broad U.S. Equity ETFs

Commodities

Federal Reserve

ETFs

$BTC

BKNG

CAKE

CARR

CBRE

EXEL

FRSH

HUBB

INCY

JBLU

MDLZ

NVDA

PYPL

QRVO

SOFI

SPOT

SRPT

XLRE

AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?

Move over, Magnificent Seven—Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) just became a solo act. The GPU giant is now worth more than double the combined market caps of Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) ($1.02 trillion), Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) ($281.57 billion), Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) ($372.58 billion) and Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) ($90.52 billion), with a towering <a href="https://www.benzinga.com/quote/NVDA/news">$4.31 trillion valuation</a>. If this isn't peak silicon supremacy, what is?



<ul class="wp-block-list">
<li>Track Nvidia&#8217;s stock surge <a href="https://www.benzinga.com/quote/NVDA">here</a>.</li>
</ul>



While competitors wrangle with execution and margins, Nvidia's AI-fueled engine hasn't missed a beat. And neither have the markets. The stock has rallied nearly 1,566% over the past five years, 58% in the last 12 months, and it shows no signs of cooling, trading at a fresh all-time high of $177 on Monday.



Read Also: <a href="https://www.benzinga.com/markets/tech/25/07/46571093/elon-musk-wants-50-million-ai-brains-nvidia-still-sets-the-standard">Elon Musk Wants 50 Million AI Brains—Nvidia Still Sets The Standard</a>



<h2 class="wp-block-heading">AI's Crown Jewel? Wall Street Thinks So</h2>



Nvidia's valuation metrics are bold, but not entirely bonkers in the age of AI. Per <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0729">Benzinga Pro</a> data, its price-to-earnings ratio sits at 57x trailing, but the forward P/E of 39.5x suggests earnings are catching up fast. A PEG ratio of 1.71 implies that even with high growth, the stock isn't outrageously priced.



Meanwhile, Nvidia's enterprise value—just a touch under its market cap at $4.27T—indicates a clean balance sheet with little debt drag. With an earnings yield of 1.75%, it&#8217;s not a cash cow like a mature tech name, but investors aren't buying Nvidia for its dividends—they're buying the future.



<h2 class="wp-block-heading">Nvidia's Rise Isn't Just Big—It's Symbolic</h2>



In a way, Nvidia overtaking Tesla, AMD, Palantir, and Intel combined feels poetic. It's not just leading the AI race—it's defining the terrain. Tesla may promise robotaxis, Palantir may promise intelligence, and AMD may promise competition—but for now, Wall Street has spoken.



The future of computing isn't coming—it's already trading at $177 a share.



Read Next: 



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46466318/nvidias-a-startup-with-apples-margins-amds-just-priced-like-one">Nvidia&#8217;s A Startup With Apple&#8217;s Margins &#8211; AMD&#8217;s Just Priced Like One</a></li>
</ul>



Photo: Shutterstock

INTC

PLTR

TSLA

Nvidia Is Now Worth Twice Tesla, AMD, Palantir, And Intel Combined

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported second-quarter 2025 earnings on Tuesday and <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46672190/unitedhealth-group-shares-flat-ahead-of-earnings-as-market-awaits-guidance" rel="noreferrer noopener">reestablished its 2025 guidance</a>.



The insurance giant reported adjusted earnings of $4.08, down from $6.80 a year ago, missing the consensus of $4.95.



Revenues increased 13% year over year to $111.62 billion, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $111.69 billion</a>.



"UnitedHealth Group has embarked on a rigorous path back to being a high-performing company&#8230;," said UnitedHealth CEO Stephen Hemsley. The company is strengthening operating disciplines, positioning itself for <a href="https://www.benzinga.com/pressreleases/25/07/b46681310/unitedhealth-group-re-establishes-full-year-outlook-and-reports-second-quarter-2025-results" target="_blank" rel="noreferrer noopener">growth in 2026 and beyond</a>, he added.



Also Read: <a href="https://www.benzinga.com/news/legal/25/07/46605691/unitedhealth-under-federal-scrutiny-reaffirms-integrity-of-its-medicare-operations" target="_blank" rel="noreferrer noopener">UnitedHealth Under Federal Scrutiny—Reaffirms Integrity Of Its Medicare Operations</a>



In addition:



<ul class="wp-block-list">
<li>Q2 medical care ratio of 89.4% increased 430 basis points year-over-year.</li>



<li>Operating cost ratio was 12.3% compared to 13.3% in the year-ago quarter reflecting business mix, inclusive of the Part D program changes, reduced impacts from last year's Change Healthcare cyberattack and cost management activities.</li>



<li>Q2 revenue was $86.1 billion, a 17% year-over-year boost. </li>



<li>The segment served 50 million people, an increase of 770,000 year-to-date.</li>



<li>Earnings from operations were $2.1 billion compared to $4.0 billion in the second quarter of 2024, and the margin fell from 5.4% to 2.4% primarily due to higher-than-expected medical cost trends across the UnitedHealthcare businesses and the effects of the Medicare funding reductions.</li>



<li>For the employer and individual segment, the number of people served increased by 400,000 year-over-year, with growth in employer self-funded offerings of 695,000 partially offset by attrition in both individual and group fully insured products.</li>



<li>The number of people served with individual and group Medicare Advantage offerings grew by 505,000 through the first half of 2025. Medicare Supplement plans contracted by 30,000, and Stand-Alone Part D plans decreased by 250,000.</li>



<li>Optum Health's revenue of $25.2 billion decreased 7% year-over-year, driven by the legacy customer contract revisions cited in the first quarter of 2025 and effects related to the Medicare Advantage funding cuts.</li>



<li>Earnings from operations were $636 million, compared to $1.9 billion in the year-ago quarter, and operating margins were 2.5% and 7.1%, respectively.</li>
</ul>



Guidance: UnitedHealth reestablished its fiscal year 2025 guidance, with adjusted earnings of at least&nbsp;$16 per share versus a consensus of&nbsp;$22.33 and sales&nbsp;guidance&nbsp;of&nbsp;$445.5 billion-$448 billion compared to the analyst estimate of $449.5 billion.



In May, UnitedHealth suspended its 2025 performance outlook.



It expected adjusted earnings of $26.00-$26.50 per share versus&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">prior guidance of $29.50-$30.00</a> per share, versus consensus of $29.73.



The full-year 2025 medical cost ratio is now expected to be 89.25% +/—25 basis points, with operating cost ratio expected to be 12.75% +/- 25 basis points.



For Optum Health: 2025 revenues are expected to be between $101.1 billion and $101.6 billion, a 4% decline from 2024, with earnings from operations of $3 billion—$3.1 billion below expectations of around $6.6 billion.



<ul class="wp-block-list">
<li>The number of patients served under fully accountable value-based care models is now expected to increase by around 300,000 to 5 million.</li>
</ul>



UnitedHealthcare&#8217;s full-year 2025 revenues are expected to range from $344 billion to $345.5 billion, growing more than 15% over 2024. Earnings from operations are expected to be in the range of $9.0 billion to $9.3 billion.



<ul class="wp-block-list">
<li>The number of people served with medical benefits is expected to increase by up to 1.135 million over 2024.</li>



<li>The number of people served with commercial benefits is expected to increase by up to 335,000, with growth of 720,000 within self-funded employer-sponsored offerings.</li>



<li>The number of people served with commercial insured offerings is expected to decline by 385,000, comprised of 180,000 contraction in individual insured offerings, of which 140,000 are on exchange products, and a decline of 205,000 in employer-sponsored group products.</li>
</ul>



During the earnings conference call, a UnitedHealth executive reportedly said the company will be more conservative with its footprint and may exit certain markets to manage its membership profile.



Price Action: UNH stock is down 4.5% at $269.41 on the last check Tuesday.



Read Next:



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46680128/self-driving-cars-could-be-200-billion-market-by-2030-says-morgan-stanley" target="_blank" rel="noreferrer noopener">Self-Driving Cars Could Be $200 Billion Market By 2030, Says Morgan Stanley</a></li>
</ul>



Image: Shutterstock

Guidance

Health Care

General

UnitedHealth Misses Q2 Mark But Vows A Healthier 2026

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) experienced a <a href="https://www.benzinga.com/topic/spotify">notable decline</a> in its stock price on Tuesday following the release of its second-quarter 2025 financial results. 



While the audio streaming giant demonstrated robust growth in its user base, a significant miss on earnings per share and revenue, coupled with a conservative outlook for the upcoming quarter, weighed heavily on investor sentiment.



For the second quarter, Spotify posted a loss of 48 cents per share, a considerable deviation from the analyst <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus estimate of a $2.11 profit</a>.



Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45798733/apple-faces-modest-earnings-hit-after-court-ruling-but-analyst-expects-match-bumble-spotify-set-to-gain" rel="noreferrer noopener">Apple Faces Modest Earnings Hit After Court Ruling But Analyst Expects Match, Bumble, Spotify To Gain</a>



This earnings shortfall was compounded by missed revenue projections, with quarterly sales <a href="https://investors.spotify.com/financials/default.aspx#quarterly-results">reaching $4.75 billion</a> (4.19 billion euros), marking a 10% year-over-year increase but falling short of the analyst projection of $4.84 billion.



<h2 class="wp-block-heading">Strong User Acquisition, But Monetization Challenges Persist</h2>



Operational highlights for the quarter included impressive user acquisition. Monthly active users (MAUs) saw a net addition of 18 million quarter-over-quarter, reaching a total of 696 million, exceeding the company&#8217;s own guidance by 7 million.



Premium subscribers also demonstrated robust growth, expanding by 12% year-over-year to 276 million, outperforming expectations by 3 million and showing consistent growth across all geographical regions.



However, a slight decline was observed in key monetization metrics, with average revenue per user (ARPU) for Premium subscribers falling 1% year-over-year to 4.57 euros, and ad-supported revenue also experiencing a 1% decrease.



From a profitability standpoint, Spotify showcased improved margins. The company&#8217;s gross margin expanded by 227 basis points year-over-year to 31.5%, driven by enhancements in both its Premium and Ad-Supported segments.



The Premium gross margin reached 33.1%, an increase of 171 basis points from the prior year, primarily attributed to revenue growth outpacing music and audiobook costs, albeit partially offset by Spotify partner program expenses.



The ad-supported gross margin saw a more substantial improvement, rising 495 basis points to 18.3%, buoyed by stronger contributions from podcasts and music.



Operating income surged by 53% year-over-year, reaching 406 million euros, with an operating margin of 9.7%. Spotify also reported a strong financial position, holding 8.4 billion euros in cash and equivalents and generating 700 million euros in free cash flow.



The company&#8217;s disciplined approach to expenses was further evidenced by a slight reduction in its global workforce, which stood at 7,309 full-time employees, down from 7,372 a year ago.



<h2 class="wp-block-heading">Conservative Q3 Outlook Weighs on Investor Sentiment</h2>



Despite these operational successes, Spotify&#8217;s third-quarter 2025 revenue outlook fell short of market expectations. The company forecasts revenue of $4.95 billion (4.2 billion euros), below the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus of $5.15 billion</a>, while anticipating total MAUs to reach 710 million.



Prior to the announcement of the 2025 second-quarter results, Spotify&#8217;s stock experienced a strong rally throughout 2025, surging 57% year-to-date and gaining 22% over the last three months.



However, the premarket trading on Tuesday saw SPOT stock trade lower by 6.99% at $652.00, reflecting investor reaction to the earnings miss and softer guidance.



Read Next:



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/07/46347606/roku-called-self-help-turnaround-citing-profit-focus-and-new-ad-partners" target="_blank" rel="noreferrer noopener">Roku Called &#8216;Self-Help&#8217; Turnaround, Citing Profit Focus And New Ad Partners</a></li>
</ul>



Photo by Diego Thomazini via Shutterstock

Spotify User Base Grows, But Profitability Concerns Linger

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), the Danish pharmaceutical giant renowned for its <a href="https://www.benzinga.com/topic/weight-loss">weight-loss</a> drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following the company&#8217;s decision to trim its 2025 financial outlook.



This marks the <a href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings">second time this year</a> the company has revised its guidance downwards, signaling growing headwinds in key markets. Novo Nordisk now projects 2025 sales growth to be in the range of 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%. 



Similarly, the outlook for operating profit growth has been lowered to 10-16% from the previously anticipated 16-24%. This revised guidance largely stems from a slower-than-expected penetration of its branded GLP-1 treatments, particularly in the United States, a market increasingly impacted by the persistent use of compounded GLP-1 alternatives.



Also Read: <a href="https://www.benzinga.com/news/legal/25/07/46635233/judge-rules-mylan-did-not-infringe-novo-nordisk-patent-in-wegovy-generic-case" target="_blank" rel="noreferrer noopener">Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case</a>



The company specifically cited lower growth expectations for Wegovy in the U.S. obesity market and for Ozempic in the U.S. GLP-1 diabetes market. Furthermore, Wegovy&#8217;s penetration in certain international markets has also fallen short of expectations, attributing to slower market expansion and heightened competition.



In May, Novo Nordisk already lowered its 2025 guidance, reflecting lower-than-planned penetration of branded GLP-1 treatments in the U.S., impacted by <a href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" target="_blank" rel="noreferrer noopener">compounded GLP-1s</a>.



Despite the expiry of the FDA&#8217;s <a href="https://www.globenewswire.com/news-release/2025/07/29/3123109/0/en/Novo-Nordisk-lowers-sales-and-operating-profit-outlook-for-2025.html">grace period</a> for mass compounding on May 22, 2025, Novo Nordisk asserts that unsafe and unlawful mass compounding has continued unabated. The company&#8217;s market research indicates that numerous entities persist in marketing and selling compounded GLP-1s under the guise of &#8220;personalization,&#8221; directly impacting Wegovy&#8217;s penetration within the cash payment channel. 



In response, Novo Nordisk has launched NovoCare Pharmacy in March 2025, which has facilitated approximately 11,000 total weekly Wegovy prescriptions, alongside an additional 20,000 weekly prescriptions in the broader retail cash channel.



In the insured channel, new commercial initiatives for Wegovy launched in the first half of 2025 have not fully offset the slower market expansion and competitive pressures, leading to lower-than-anticipated penetration.



To counter these challenges, Novo Nordisk is actively pursuing multiple strategies, including litigation, to safeguard patients from what it terms &#8220;knockoff &#8216;semaglutide&#8217; drugs.&#8221; This comes amid a broader industry concern, highlighted by a recent letter from over 80 bipartisan U.S. congressional members to FDA Commissioner Marty Makary, urging the agency to curb the proliferation of <a href="https://www.benzinga.com/news/fda/25/07/46641326/congress-sounds-alarm-over-illegal-weight-loss-drug-imports-from-china">counterfeit and copycat</a> GLP-1 drugs.



On a more positive note, Novo Nordisk anticipates a beneficial impact from changes to CVS&#8217;s <a href="https://www.benzinga.com/general/health-care/25/05/45140567/cvs-health-partners-with-wegovy-maker-novo-nordisk-hikes-2025-guidance">national template formulary</a>, effective July 1, 2025, where Wegovy is now the sole GLP-1 medication covered for obesity. The company also continues to invest in commercial activities and label updates to enhance Ozempic&#8217;s market penetration, despite increased competition in the U.S.



Internationally, while Wegovy sales are experiencing robust growth rates and launches are progressing, the revised outlook reflects lower-than-expected penetration in select markets due to slower expansion and competition.



For the first six months of 2025, Novo Nordisk reported an 18% increase in sales and a 29% rise in operating profit at constant exchange rates. These figures were positively influenced by gross-to-net sales adjustments related to prior years, including a significant adjustment of approximately $450 million (3 billion Danish kroner) in the second quarter of 2025 pertaining to the 340B provision. Operating profit growth also benefited from the reversal of an ocedurenone impairment in the second quarter of 2024, partially offset by impacts from the acquisition of three Catalent manufacturing sites.



The company&#8217;s free cash flow is now expected to be in the range of 35-45 billion Danish kroner, a revision reflecting the lower projected sales growth, primarily driven by reduced volume growth of GLP-1-based treatments in the U.S. and associated cash flow implications, further amplified by the intricacies of the U.S. gross-to-net system.



In a key regulatory development, Novo Nordisk expects a regulatory decision regarding the Wegovy Metabolic Dysfunction-Associated Steatohepatitis (MASH) indication during the second half of 2025, which could potentially open up a significant new market for the drug.



<h2 class="wp-block-heading">Leadership Transition</h2>



Adding to the day&#8217;s significant announcements, Novo Nordisk also revealed a leadership change. Maziar Mike Doustdar has been appointed as the new president and chief executive officer, effective August 7, 2025. 



Doustdar, currently Novo Nordisk&#8217;s Executive Vice President of International Operations, will succeed Lars Fruergaard Jørgensen, who will be stepping down from his role.



Price Action: In premarket trading on Tuesday, Novo Nordisk&#8217;s stock plummeted 18.5% to $56.21, reflecting investor apprehension regarding the revised financial projections and the ongoing challenges posed by the compounded drug market.



Read Next:



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46683019/byd-surpasses-tesla-in-fortune-global-500-list-amid-sales-slump-for-elon-musks-ev-giant" target="_blank" rel="noreferrer noopener">BYD Surpasses Tesla In Fortune Global 500 List Amid Sales Slump For Elon Musk&#8217;s EV Giant</a></li>
</ul>



Image by KK Stock via Shutterstock

Biotech

Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO

U.S. stock futures rose on Tuesday after ending on a mixed note on Monday. Futures of major benchmark indices were higher.



Despite a mixed close, the S&amp;P 500 posted its sixth day of record closing high, and the Nasdaq also notched an all-time high on Monday.



The Federal Reserve Open Market Committee&#8217;s two-day meeting will begin today, ahead of its press conference, which will be held on Wednesday afternoon.



Investors await results from Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), and Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) today.



Meanwhile, the 10-year Treasury bond yielded 4.41% and the two-year bond was at 3.92%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 96.9% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting.



<figure class="wp-block-table is-style-stripes"><table class="has-fixed-layout"><tbody><tr><td>Futures</td><td>Change (+/-)</td></tr><tr><td>Dow Jones</td><td>0.15%</td></tr><tr><td>S&amp;P 500</td><td>0.24%</td></tr><tr><td>Nasdaq 100</td><td>0.41%</td></tr><tr><td>Russell 2000</td><td>0.31%</td></tr></tbody></table></figure>



The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Friday. The SPY was up 0.23% at $638.40, while the QQQ advanced 0.42% to $570.54, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.



Cues From Last Session:



On Monday, the energy and information technology sectors on the S&amp;P 500 closed higher, bucking the trend as most sectors, including real estate, materials, and utilities, recorded losses.



This occurred as U.S. stocks settled mixed, with the S&amp;P 500 itself recording gains, as markets reacted to the U.S.-EU trade deal struck over the weekend.



The new agreement means the U.S. will impose a 15% tariff on EU imports like pharmaceuticals and automobiles, while certain sectors such as steel, aluminum, and copper will face steeper tariffs of up to 50%.



All three major indices closed the last week higher, with the 30-stock Dow gaining around 1.3% and the tech-heavy Nasdaq adding 1%. The broad market S&amp;P 500 climbed around 1.5% last week.



Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped 3% after the U.S. announced lower-than-expected tariffs on European goods, including autos, and following CEO Elon Musk's revelation of a $16.5 billion deal with Samsung Electronics to produce next-generation chips.



<figure class="wp-block-table is-style-stripes"><table class="has-fixed-layout"><tbody><tr><td>Index</td><td>Performance (+/-)</td><td>Value</td></tr><tr><td>Nasdaq Composite</td><td>0.33%</td><td>21,178.58</td></tr><tr><td>S&amp;P 500</td><td>0.018%</td><td>6,389.77</td></tr><tr><td>Dow Jones</td><td>-0.14%</td><td>44,837.56</td></tr><tr><td>Russell 2000</td><td>-0.19%</td><td>2,256.73</td></tr></tbody></table></figure>



Insights From Analysts:



Senior Economist Jeremy Siegel highlighted in his weekly commentary that the U.S. economy is still proving resilient despite global tensions and trade barriers.



However, he cautioned that investors should prepare for some economic drag as these tariffs take hold in the second half of the year. &#8220;The cumulative inflation impact from tariffs is likely to be modest, perhaps 1.5% to 2% over two years, while the GDP drag remains limited and manageable,&#8221; he said.



He explained that the market has come to terms with this dynamic and continues to look ahead to more powerful, longer-term forces, particularly the ongoing AI.



&#8220;I think the market rightly assesses this will buoy productivity and earnings. In particular, the immediate expensing provision for capital equipment that came in the ‘One Big Beautiful Bill' is a meaningful tailwind for corporate investment, counteracting some negative tariff effects.&#8221;



According to him, earnings season is not showing signs of a breakdown. While there is some cautious forward guidance, the tone has been far more constructive than feared. &#8220;I'm encouraged by year-end earnings estimates, which remain stable or even modestly positive. I continue to believe we are in a healthy bull market with no signs of internal deterioration,&#8221; he added.



From a valuation perspective, Siegel said that some argue markets are expensive.



&#8220;When measuring forward P/E ratios, we are increasingly pricing in next year's earnings, which are supported by strong productivity trends and expanding technology adoption. The 2025–2026 EPS outlook is solid, and while earnings might come down from lofty year-ahead outlooks, I continue to see upside in equities,&#8221; he added.



Meanwhile, Ryan Detrick from Carson Research also reiterated that the market rally has been &#8220;historic,&#8221; but it &#8220;likely has legs left.&#8221;



<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Don&#39;t stop believing. This rally has been historic, but it likely has legs left. Talking with <a href="https://twitter.com/sonusvarghese?ref_src=twsrc%5Etfw">@sonusvarghese</a> about it all in our latest Facts vs Feelings &#x1f440; <a href="https://t.co/yzIlXWwqbZ">https://t.co/yzIlXWwqbZ</a> &#x1f3a7;<a href="https://t.co/rbZGmRxOa1">https://t.co/rbZGmRxOa1</a> <a href="https://t.co/5vPmnmJOOx">pic.twitter.com/5vPmnmJOOx</a>&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1950002858570494054?ref_src=twsrc%5Etfw">July 29, 2025</a></blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
</div></figure>



See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 



Upcoming Economic Data



Here&#8217;s what investors will keep an eye on Tuesday:



<ul class="wp-block-list">
<li>June&#8217;s advanced U.S. trade balance in goods, retail inventories, and wholesale inventories data will be announced by 8:30 a.m. ET.</li>



<li>May&#8217;s S&amp;P Case-Shiller home price index for 20 cities will be out by 9:00 a.m., July&#8217;s consumer confidence data, and June&#8217;s job openings data will be released by 10:00 a.m. ET.</li>
</ul>



Stocks In Focus:



<ul class="wp-block-list">
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) was up 0.14% in premarket on Tuesday as analysts expect it to report a quarterly loss of 94 cents per share on revenue of $20.20 billion before the opening bell.</li>



<li>Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) declined 0.41% as it is expected to report earnings before the opening bell. Analysts estimate earnings of $1.42 per share on revenue of $20.76 billion.</li>



<li>Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) was 0.18% higher as analysts expect it to report earnings of 65 cents per share on revenue of $9.29 billion after the closing bell.</li>



<li>Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) rose 0.48% after posting upbeat earnings for the second quarter, but lowered its FY2025 sales guidance.</li>



<li>Koninklijke Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) jumped 9.31% after posting better-than-expected earnings for the second quarter. Philips posted quarterly adjusted earnings of 41 cents per share, beating market estimates of 29 cents per share.</li>



<li>Cadence Design Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) climbed 6.52% after it lifted its full-year outlook after the second quarter results topped estimates.</li>



<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 1.75% following the news of a new strategic partnership and reports of softened trade enforcement between the U.S. and China.</li>



<li>VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) tumbled 6.20% after declaring that its board has approved a stock repurchase plan of up to $1.11 billion in shares.</li>
</ul>



Commodities, Gold, And Global Equity Markets:



Crude oil futures were trading higher in the early New York session by 0.79% to hover around $67.24 per barrel.



Gold Spot US Dollar rose 0.23% to hover around $3,322.20 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.17% at the 98.7980 level.



Asian markets mostly advanced on Tuesday, except Japan's Nikkei 225 and Hong Kong's Hang Seng indices. South Korea's Kospi, India's S&amp;P BSE Sensex, China&#8217;s CSI 300, and Australia's ASX 200 indices rose. European markets were mostly higher in early trade.



Read Next:



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46679779/opendoor-skyrockets-314-in-a-month-amid-meme-stock-mania-hedge-fund-manager-who-reaped-windfall-gains-says-im-not-here-to-pump-up-a-stock">Opendoor Skyrockets 314% In A Month Amid Meme Stock Mania: Hedge Fund Manager Who Reaped Windfall Gains Says &#8216;I&#8217;m Not Here To Pump Up A Stock&#8217;</a></li>
</ul>



Photo courtesy: Shutterstock

CDNS

SMCI

VRSN

Stock Market Today: US Futures Rise Following S&P 500's 6-Days Of Record Close—Boeing, P&G, Starbucks Earnings In Focus

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) will close one of its retail locations in China next month, marking the first store closure in the country since the tech giant entered the market in 2008.



What Happened: On Monday, the company announced it will shut down its store at Parkland Mall in Dalian City's Zhongshan District on Aug. 9, citing a broader decline in the mall&#8217;s retail presence, <a href="https://www.nytimes.com/2025/07/29/business/apple-china-dalian-store.html">reported</a> the New York Times.&nbsp;



Several major brands, including Michael Kors and Armani, have already exited the location, and locals have described the mall as struggling.



"Given the departure of several retailers at the Parkland Mall, we have made the decision to close our store," said Apple spokesperson Brian Bumbery in a statement. "We love serving the Dalian community, and all of our valued team members will have the opportunity to continue their roles with Apple."



See Read:&nbsp;<a href="https://www.benzinga.com/news/topics/25/07/46383701/apple-undergoing-major-management-overhaul-but-ceo-tim-cook-to-stay-on" target="_blank" rel="noreferrer noopener">Apple Undergoing Major Management Overhaul, But CEO Tim Cook To Stay On</a>



The company said it will continue operating its second Dalian location at Olympia 66 and remains committed to its presence in the region. A new Apple Store is set to open in Shenzhen later this month.



Why It's Important: The closure signals growing challenges for Apple in its second-largest market, where it has reported six consecutive quarters of declining sales.



Last year, revenue from Greater China fell to $66.95 billion, down nearly 10% from its 2022 peak.



Apple is also under <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45930835/iphone-sales-rebound-in-china-but-apples-next-move-could-be-risky">increasing pressure</a> from Chinese smartphone competitors such as Huawei Technologies, Xiaomi (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) and Vivo, which have eaten into its market share.



According to Counterpoint Research, Apple's share of China's smartphone market dropped to 15.5% in 2024, down from 17.9% the year before.



With the Parkland Mall closure, Apple will still end 2025 with 58 stores in China, maintaining its current store count despite the strategic exit.



Price Action: Apple shares inched up 0.079% during Monday's regular session and rose another 0.028% after hours, according to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0717">Benzinga Pro</a>.



Benzinga's Edge Stock Rankings indicate that AAPL shows strong momentum over the short and medium term, though it trends downward over the long run. Despite boasting a solid quality score, the stock continues to carry a relatively weak value rating. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">More detailed performance insights are available here</a>.



<figure class="wp-block-image aligncenter size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29040330/Screenshot-2025-07-29-at-1.31.21%E2%80%AFPM.png" alt="" class="wp-image-1004623"/></a></figure>



Read Next



<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45852024/apples-liquid-glass-interface-set-to-revolutionize-ios-26-hints-at-20th-anniversary-iphone" target="_blank" rel="noreferrer noopener">Apple&#8217;s Liquid Glass Interface Set To Revolutionize iOS 26, Hints At 20th Anniversary iPhone</a></li>
</ul>



Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.



Photo courtesy: Shutterstock

XIACF

Apple To Shut Down China Retail Store For First Time Ever, Citing Shifting Mall Landscape Amid Consumer Slowdown

The Symbol FXCOF was not found. Here are some similar symbols and popular symbols to consider.

FXCOF Page Not Found - Benzinga

Symbol Similar to: FXCOF

Top Gaining Stocks

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL